NCT00808509View on ClinicalTrials.gov

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

adalimumab

40 mg every other week via subcutaneous injection

DRUG

methotrexate

At least 10 mg/week administered orally or subcutaneously

Trial Locations (8)

20502

Site Reference ID/Investigator# 14023, Malmo

22185

Site Reference ID/Investigator# 14022, Lund

31392

Site Reference ID/Investigator# 14301, Oskarström

54185

Site Reference ID/Investigator# 20241, Skövde

75185

Site Reference ID/Investigator# 14302, Uppsala

581 85

Site Reference ID/Investigator# 22062, Linköping

171 76

Site Reference ID/Investigator# 4918, Stockholm

SE-141 86

Site Reference ID/Investigator# 14021, Stockholm

Sponsors
All Listed Sponsors
collaborator

Pharma Consulting Group AB

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00808509 - A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission | Biotech Hunter | Biotech Hunter